Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Down 9.3% in March

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) saw a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 220,400 shares, a decline of 9.3% from the March 15th total of 242,900 shares. Based on an average trading volume of 70,600 shares, the short-interest ratio is presently 3.1 days. Approximately 1.0% of the shares of the company are short sold.

Institutional Investors Weigh In On Eton Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP bought a new stake in shares of Eton Pharmaceuticals during the fourth quarter valued at approximately $46,000. Virtu Financial LLC bought a new stake in shares of Eton Pharmaceuticals during the fourth quarter valued at approximately $57,000. Renaissance Technologies LLC bought a new stake in shares of Eton Pharmaceuticals during the first quarter valued at approximately $52,000. Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals during the fourth quarter valued at approximately $43,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Eton Pharmaceuticals during the first quarter valued at approximately $77,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Performance

ETON stock traded down $0.05 during midday trading on Wednesday, reaching $3.14. The company had a trading volume of 94,860 shares, compared to its average volume of 69,196. The stock has a 50 day moving average price of $4.06 and a 200 day moving average price of $4.13. Eton Pharmaceuticals has a fifty-two week low of $2.42 and a fifty-two week high of $5.81.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its earnings results on Thursday, March 14th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.05). Eton Pharmaceuticals had a negative net margin of 2.96% and a negative return on equity of 6.21%. The company had revenue of $7.31 million during the quarter, compared to analyst estimates of $7.70 million. As a group, analysts anticipate that Eton Pharmaceuticals will post 0.26 EPS for the current year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.